10 Results for "

wild-type JAK2

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "wild-type JAK2" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-16379
CAS No.: 937272-79-2
Synonyms: SB1518
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM).
loading...
    loading...
20
20 Publications Verification
Cat. No.: HY-16379B
CAS No.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-13775
CAS No.: 945755-56-6
Purity:  99.65%
Target:  

JAK Apoptosis

Research Areas:  

Cancer

XL019?is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .
loading...
    loading...
Cat. No.: HY-164393
CAS No.: 1035199-04-2
Target:  

JAK Bcr-Abl Apoptosis

Research Areas:  

Cancer

ON044580 is a non–ATP-competitive JAK2 and BCR-ABL kinases inhibitor. ON044580 inhibits wild-type (WT) and V617F mutant JAK2 with IC50 values of 1.23 μM, 1.09 μM, respectively. ON044580 also inhibits both WT and T315I mutant BCR-ABL kinases., ON044580 blocks the IL-3–mediated phosphorylation of JAK2 and STAT5, induces apoptosis in Imatinib (HY-15463)-resistant chronic myeloid leukemia (CML). ON044580 can be used for the study of CML, myelodysplasia (MDS) and other myeloproliferative neoplasms .
loading...
    loading...
Cat. No.: HY-16379S
Synonyms: SB1518-d4
Pacritinib-d8 (SB1518-d8) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM).
loading...
    loading...
Cat. No.: HY-16379A
CAS No.: 1228923-43-0
Synonyms: SB1518 hydrochloride
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .
loading...
    loading...
Cat. No.: HY-16379R
CAS No.: 937272-79-2
Synonyms: SB1518 (Standard)
Research Areas:  

Cancer

Pacritinib (Standard) is the analytical standard of Pacritinib. This product is intended for research and analytical applications. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).
loading...
    loading...
Cat. No.: HY-180561
CAS No.: 3076807-15-0
Research Areas:  

Cancer

WWQ-03-012 is a selective DESI2 inhibitor with an IC50 of 47.3 nM. WWQ-03-012 binds covalently to DESI2, blocks its enzymatic activity, and inhibits DESI2-mediated deSUMOylation, deubiquitination and stabilization of mutant JAK2, thereby promoting the complete degradation of mutant JAK2 via the intracellular ubiquitin-proteasome system and inducing apoptosis, while exerting no significant effect on wild-type JAK2. WWQ-03-012 can be used for research on myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML), especially for hematological malignancies carrying the JAK2-V617F mutation and those resistant to Ruxolitinib (HY-50856) .
loading...
    loading...
Cat. No.: HY-188002
CAS No.: 3057053-16-1
Target:  

JAK

Research Areas:  

Cancer

JAK2-IN-23 is a highly selective JH2-binding JAK2 inhibitor, with an IC50 ≤ 10 nM for binding to both wild-type and V617F-mutated JH2. JAK2-IN-23 can be used in studies of JAK2-related diseases, such as cancer .
loading...
    loading...
Cat. No.: HY-188001
CAS No.: 3057053-13-8
Target:  

JAK

Research Areas:  

Cancer

JAK2-IN-22 is a bicyclic urea compound with potent binding inhibitory activity against wild-type and V617F mutant JH2 kinases (IC50 ≤ 10 nM). JAK2-IN-22 can be used in research related to various diseases including cancer .
loading...
    loading...